cyrilzakka/clinical-trials huggingface dataset:
Visual Analogue Scale - a Quality Assurance Study

It has come to our attention that there is not a general consensus of how to apply Visual Analogue Scale (VAS) as a tool in measuring pain amongst postoperative patients in Denmark.

The assumption is that patients will grade the level of pain differently dependent on how VAS is presented.

To ensure the data is valid for the study it has been decided to base the research material on four different VAS usage, as it is most often used in clinical practise in Denmark. Which in this case implies VAS horizontal, with and without endpoint, and VAS vertical, with and without endpoint. Every participant will grade their pain on each of the listed VAS representations. Furthermore, as a guideline, the participant will be asked to grade the pain on a Numerical Ranking Scale (NRS).

The ordering of VAS lines will be subject to randomization, for each participant

Eligibility Criteria:
Inclusion Criteria:

* Patient must have undergone surgery within the last five days
* The patient must be able and willing to participate in the study
* Must be at 18 years of age or older
* A patient can only participate one time.

Exclusion Criteria:

* Previously included patients
* Medically treated patients Linguistic difficulties
* Mentally or physically exhausted
Effects of Gluten-Free Diet on Nutritional Status in Celiac Patients

This study examined the impact of a gluten-free diet on nutritional status and inflammation markers in adult celiac patients compared to a control group. Twenty-six celiac patients and 26 healthy individuals participated. Interviews, dietary records, anthropometric measurements, and blood samples were collected. After six weeks, celiac patients showed improved adherence to the gluten-free diet and increased quality of life scores. While initial micronutrient intake was lower in celiac patients, it improved over the study period. However, there were no significant changes in inflammation markers.

This study aimed to examine the effects of a gluten-free diet on the nutritional status, anthropometric measurements, and serum levels of interferon-gamma (IFN-γ) and interleukin-15 (IL-15) in adult celiac patients, comparing them with a control group. A total of 26 celiac patients aged 18-64 years and 26 healthy individuals as the control group were included. Face-to-face interviews were conducted to determine participants\&#39; general characteristics, dietary habits, and physical activity status. Additionally, a retrospective 24-hour dietary recall and food frequency questionnaire were administered to assess dietary intake. Anthropometric measurements and blood samples were collected during the interviews. Celiac patients received education about the gluten-free diet, and follow-up assessments were conducted six weeks later. At the beginning, 53.8% of celiac patients reported always/mostly adhering to the gluten-free diet, which increased to 100.0% after six weeks. The total quality of life scores significantly increased in celiac patients after six weeks. Initial serum IL-15 levels were similar between celiac and control groups, whereas serum IFN-γ levels were significantly higher in celiac patients compared to the control group.

Eligibility Criteria:
Inclusion Criteria:

* Adults aged between 19 and 64 years old.
* Diagnosis of celiac disease.
* Willingness to participate in the study.
* Ability to adhere to the study protocol, including dietary restrictions and follow-up assessments.
* For the control group, individuals without celiac disease or any other significant health conditions.

Exclusion Criteria:

* Individuals following diets other than a gluten-free diet.
* Individuals adhering to a gluten-free diet for reasons other than celiac disease.
* Individuals with gastrointestinal diseases other than celiac disease.
* Individuals who have undergone gastrointestinal surgery.
* Individuals with mental illnesses.
* Cancer patients.
* Individuals positive for hepatitis B surface antigen or anti-hepatitis C virus antibody.
* Individuals using interferon and/or insulin.
* Pregnant or lactating women.
Clinical Research of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy

H3F3AK27M may be a feature of primary spinal cord glioma and affect the outcome and prognosis of TMZ chemoradiotherapy.


Eligibility Criteria:
Inclusion Criteria:

* Surgical treatment and pathological confirmation of spinal glioma in our department and is the first case without any treatment before operation.

Exclusion Criteria:

* The tumor is recurrent or has been treated before operation.
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

The purpose of the study is to test the safety and dosing of \[177Lu\]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and alpha-v beta-5 integrin (αvβ5). The study will also further characterize the radioligand imaging agent \[68Ga\]Ga-FF58 including its ability to identify tumor lesions and its safety profile.

The study will be done in two parts. The first part is called "escalation" and the second part is called "expansion". In both parts of the study, patients will be screened with a \[68Ga\]Ga-FF58 positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) scan to assess eligibility for treatment with \[177Lu\]Lu-FF58. In the escalation part, different doses of \[177Lu\]Lu-FF58 will be tested to identify the recommended dose. The expansion part of the study will examine the safety and preliminary efficacy of \[177Lu\]Lu-FF58 at the recommended dose determined during the escalation part. The end of study will occur when at least 80% of the patients in the expansion part have completed the follow-up for disease progression or discontinued from the study for any reason, and all patients have completed treatment and the 36 month long term follow- up period, or the study is terminated early in which case all patients would also be followed up for safety.

Eligibility Criteria:
Key Inclusion criteria

* Age \>= 18 years old
* Patients with locally advanced unresectable or metastatic PDAC, locally advanced unresectable or metastatic GEA, or recurrent GBM
* To be treated with \[177Lu\]Lu-FF58, patients must have at least one measurable lesion that shows \[68Ga\]Ga-FF58 uptake on PET/CT or PET/MRI

Key Exclusion criteria

* Absolute neutrophil count (ANC) \< 1.5 x 109/L, hemoglobin \< 10 g/dL, or platelet count \< 100 x 109/L
* Prior external beam radiation therapy (EBRT) to \> 25% of the bone marrow
* Creatinine clearance \< 60 mL/min
* Unmanageable bladder outflow obstruction or urinary incontinence
* Non-GBM patients: Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within 1 week before \[177Lu\]Lu-FF58 administration

Other protocol-defined inclusion/exclusion criteria may apply
The Effect of the Educatıon and Counselıng of Prostatectomy Patıents

The research was planned as a randomized controlled experimental study. This study is planned to be conducted in the Urology clinic of a university hospital located in the south of Turkey. The population of the research will be the patients admitted to the urology clinic for prostatectomy. The sample of the study will consist of patients who meet the criteria for participation in the study and volunteer to participate in the study. Evaluation of the research data will be done with the SPSS package program.


Eligibility Criteria:
Inclusion Criteria:

* Being 18 years or older,
* Being literate,
* Being able to understand and speak Turkish and not have a hearing impairment,
* Agreeing to participate in the research.

Exclusion Criteria:

* Development of any complications during the surgical intervention,
* Having any psychiatric disorder that will reduce the ability to comprehend and understand,
* Having other concomitant cancer,
* Having metastases.
Diagnosis and Treatment of Foreign Bodies Outside Pharynx and Esophagus Lumen

Objective: To improve the success rate of the treatment of migrating foreign bodies in the upper aerodigestive tract.

Methods: The medical records of inpatients conforming to the diagnosis of migrating foreign bodies between 2020 and 2025 were reviewed. Data regarding age, gender, time from onset to hospitalization, computed tomography (CT) and endoscopic scans, surgical procedures，and follow-up were collected.


Eligibility Criteria:
Inclusion Criteria:

* The foreign body of pharynx or esophagus was confirmed by surgical exploration

Exclusion Criteria:

* The foreign body is in the pharynx or esophagus or is not found during surgery.
Actinic Cheilitis Pre-Treated With DNA Repair Enzyme Cream

It is well known that ultraviolet (UV) light causes sunburn and DNA damage that can lead to skin cancer. Despite preventative measures of sunscreens and other topicals the incidence of skin cancers continues to increase every year. Chronic exposure can lead to development of both basal and squamous cell carcinoma that also is correlated to the risk of melanoma. When epidermal keratinocytes are exposed to UV radiation, they form cyclobutane pyrimidine dimmers (CPDs), 6-pyrimidine-4-pyrimidones (6-4-PPs), and oxygen radicals that alter the structure of nucleotides. When these lesions are not repaired, DNA replication is altered that leads to mutations in p53 and PTCH tumor suppressor gene and ultimately tumor development. It has been discovered that intracellular delivery of bacterial DNA incision repair enzyme T4 endonuclease V DNA repair enzymes can repair sun induced damaged DNA in patients with xeroderma pigmentosum4,. Yarosh et al also showed that T4 endonuclease V DNA repair enzymes are specific to reducing the amount of cyclobutane pyrimidine dimers and were found to lower the rate of new actinic keratoses compared to placebo lotion by 68% with no adverse effects observed. Additionally Yarosh et al also showed that T4N5 liposomes can repair keratinocyte DNA in skin cancer patients. This study will examine if pretreating actinic cheilitis with DNA repair enzyme cream before standard treatments can decrease the need for additional and possibly more aggressive therapies, decrease the surface area of affected areas, and possibly improve skin thickening and texture.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older with clinically confirmed actinic cheilitis
* Fitzpatrick Type I, II, III, or IV skin.
* At least 20% of upper and/or lower lip affected by actinic cheilitis

Exclusion Criteria:

* Pregnant or nursing
* Allergies to any component of the study topical medication
* Prior treatment of actinic cheilitis within the past month, including cryotherapy, PDT, 5-FU, Picato, Retinoid, Diclofenac
* Prior ablative laser therapy to the lips, including fractional erbium and CO2 lasers.
* Prior use of lip fillers
* Presence of any skin disease that might interfere with the study treatments, including, but not limited to, rosacea, atopic dermatitis, lip lickers dermatitis, perioral dermatitis, perleche, active herpes infection.
* Presence of hypertrophic and hyperkeratotic lesions or cutaneous horns within the treatment area
* Any diagnosis of active, untreated skin cancer of the lip
Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.

1. LDL-C after 12 weeks of treatment
2. Safety and tolerability
3. Plasma levels of SLx-4090

Eligibility Criteria:
Inclusion Criteria:

* LDL-C \> or = 100 mg/dL
* On stable statin therapy for at least 6 weeks

Exclusion Criteria:

* Coronary heart disease or risk factors for CHD
Exercise in Pregnancy Evaluative Controlled Study

This study aimed to investigate whether there are measurable differences in CHANS function in pregnant women who receive only standard antenatal care compared with those who additionally undertake a programme of regular physical exercise.

The health benefits of physical exercise in the non-pregnant population are generally appreciated but its influence during pregnancy has not been clearly demonstrated. The focus of this proposal is to obtain for the first time a comprehensive understanding of the influence of regular physical exercise during pregnancy on cardiovascular, haemodynamic and autonomic nervous system (CHANS) parameters during pregnancy and following childbirth. This will involve assessing heart rate variability and cardiac stroke volume. This study will allow the investigators to compare CHANS parameters in pregnant women who are randomly assigned into three groups: a 'standard care' group and two groups who engage in a supervised programme of physical exercise (either land-based or water-based). The investigators will assess CHANS parameters at three stages during pregnancy and on one occasion following childbirth. This will allow the influence of regular (weekly) physical exercise on CHANS physiology to be assessed during advancing gestation. The investigators will thus use this study to provide initial evidence of the health benefits of regular and specific forms of antenatal physical exercise.

Eligibility Criteria:
Inclusion Criteria:

* Eligible participants were apparently healthy pregnant women aged 18 years or over, with no existing complications of pregnancy at their 12-week dating scan.

Exclusion Criteria:

* Exclusion criteria were: a history of cardiovascular or chronic respiratory problems, sleep apnoea, or central/peripheral nervous system disorder.
Comparing Interactive and Non-interactive CD-based Method

Using different methods of electronic learning has been increasingly developed by emerging electronic educational technologies. They could apply on the net, CDs, Mobile, etc in different usage alternatives: interactive and non-interactive both in online and off-line approaches. In this educational trial, the interactive and non-interactive CD-based method for teaching medical terminology to nursing students of MUMS school of nursing and Midwifery during 2009-2012 was compared.


Eligibility Criteria:
Inclusion Criteria:

* Nursing students studying in MUMS school of nursing and passing Medical Terminology

Exclusion Criteria:

* any other discipline,
* students of other schools
Prevelance of Frailty and Its Associated Factors in Patients With Axial Spondyloarthritis

Axial Spondyloarthritis is an inflammatory arthritis disease and its main symptoms are chronic pain and stiffness, causing structural damage to the spinal vertebrae. Axial Spondyloarthritis leads to physical disability and a decrease in the level of physical activity.

Frailty is a syndrome characterized by decline in physiological reserve and loss of muscle strength. Frailty can lead to vulnerability of individuals to possible injuries and a decrease in independence, and ultimately an increase in mortality. Although frailty is associated with older adults, it has been reported that it can be detected in patients with cancer, diabetes and rheumatological diseases and it is not related with age. Frailty has been reported to be a reversible and a treatable condition.

The aim of our study was to investigate the prevalence of frailty and the relationship between frailty and disease activity, physical functional level, quality of life and other associated factors in individuals with Axial Spondyloarthritis.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with Axial Spondyloarthritis by an experienced rheumatologist.
* To be between the ages of 40-65

Exclusion Criteria:

* Severe comorbidities such as cancer and stroke
* Being diagnosed with newly defined or recurrent cancer,
* Not having enough cognitive skills to answer the questions,
* Having neurological problems such as stroke
* Having cognitive impariment
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.

This phase 2, multicenter, open-label study is designed to assess the safety and efficacy of lurbinectedin monotherapy in 3 cohorts of participants with high-unmet medical need: advanced (metastatic and/or unresectable) urothelial cancer (UC), poorly differentiated neuroendocrine carcinomas (PD-NEC), and a homologous recombination deficient-positive malignancies agnostic cohort.

Eligibility Criteria:
Inclusion Criteria:

1. Signed informed consent
2. ≥ 18 years of age
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
4. Adequate organ and bone marrow function
5. Has measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
6. Have advanced (metastatic/unresectable) cancers in one of the following:

   1. Histologically or cytologically confirmed urothelial cancer
   2. Histologically or cytologically confirmed poorly differentiated neuroendocrine carcinoma
   3. Histologically or cytologically confirmed homologous recombination deficient-positive malignancies agnostic, which may include endometrial, biliary tract, urothelial, breast (TNBC or HR+HER2- breast cancer), pancreas, gastric, or esophageal solid tumors with preidentified germline and/or somatic pathogenic mutation
7. Adequate contraceptive precautions

Exclusion Criteria:

1. Known symptomatic central nervous system (CNS) metastasis requiring steroids
2. History of prior malignancy within 2 years of enrollment
3. Clinically significant cardiovascular disease
4. Active infection requiring systemic therapy
5. Significant non-neoplastic liver disease
6. Prior treatment with trabectedin or lurbinectedin
7. Treatment with an investigational agent within 4 weeks of enrollment
8. Received live vaccine with 4 weeks of first dose
9. Prior allogeneic bone marrow or solid organ transplant
10. Positive hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening
11. Positive human immunodeficiency virus (HIV) infection at screening
BeyondSilos - More Personalised and Coordinated Care and Improved Outcomes for Elderly Patients

The study evaluates the impact of the new organisational models developed in the framework of the BeyondSilos pilot service in order to provide ICT supported integrated health and social care to elderly patients

The overall aim of the evaluation carried out in BeyondSilos is to identify the differences introduced by implementing ICT supported integrated care in different domains according to the MAST evaluation framework, including safety, clinical and social outcomes, resource use and cost of care, user/carer experience and organisational changes.

The focus of the evaluation will be the impact of so called "horizontal" integration, which is the integration between social care and health care, and the changing organisational models for elderly patients.

The hypothesis in this study is that integrated care (IC) will lead to a more personalised and coordinated care, improve outcomes for elderly patients, deliver more effective care and support, and provide more cost efficient health and social services.

Eligibility Criteria:
Potential participants are selected by screening electronic healthcare and social care records or/and the hospital / national databases and/or during long term condition annual reviews in the community setting. If necessary, candidates are informed about the nature and the objectives of the evaluation. If a candidate passes the inclusion/exclusion criteria and signs the informed consent form, if necessary, they participate in the evaluation.

Inclusion Criteria:

* Age ≥65 years.
* Presence of health needs specified as: Presence of heart failure, stroke, COPD or diabetes (diagnosed at hospital or at specialist visit) plus at least one additional chronic disease / condition included in the Charlson Comorbidity Index (CCI).
* Presence of social needs based on Barthel Index of Activities of Daily Living and Instrumental Activities of Daily Living (IADL).
* Reasonable expectation of permanence in the BeyondSilos project for the whole data collection period (18 months).
* Informed consent, signed if necessary (by the subject or his/her delegate).
* Capability to handle ICT equipment / devices alone, or with the help from a delegate.
* Presence of good/reliable communication connection at home (internet, telephone or what is needed for the ICT connection).

Exclusion Criteria:

Subjects who have been registered with an active cancer diagnosis and undergoing treatment, has undergone an organ transplant, or is undergoing dialysis prior to enrolment.

* Subjects in a terminal state
* People with an AIDS diagnose.
Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)

This is a 28-day, placebo controlled clinical study assessing the safety, tolerability anti-inflammatory effect and pharmacokinetics of SB681323 in patients with COPD (Chronic Obstructive Pulmonary Disease).


Eligibility Criteria:
Inclusion criteria:

* Non-childbearing potential.
* Clinical diagnosis of COPD.
* Cigarette smoking history of greater than or equal to 10 pack years.
* Post-bronchodilator FEV1 to FVC ratio (FEV1:FVC) \< 0.7
* Post-bronchodilator FEV1 50% - 80% of predicted normal.
* Receiving inhaled corticosteroids for a minimum of 6 weeks prior to Screening.
* Serum CRP concentration greater than 3mg/L.

Exclusion criteria:

* Current diagnosis of asthma.
* Active tuberculosis, sarcoidosis or bronchiectasis.
* History of any type of malignancy, rheumatoid arthritis or other conditions associated with chronic inflammation.
* Clinically significant renal or hepatic disease.
* History of increased liver function tests, or patients receiving hormone replacement therapy, statins or systemic or topical corticosteroids.
Associations Between Depression and Cardiovascular Disease - a Study of Patients With Late Onset Depression

Studies show that depression is a risk factor for the development of coronary artery disease (CAD). Furthermore there is an increased occurrence of depression in patients with CAD. Among other mechanisms atherosclerosis is believed to play a central role regarding these notable associations between depression and CAD. Moreover, patients with late onset major depression have an increased number of small lesions found in the white matter of the brain, the so-called white matter lesions. The main goal of this project is to examine if CAD is associated with depression and/or white matter lesions. CAD is evaluated using coronary CT angiography. Depression is evaluated using a semi-structured diagnostic interview. White matter lesions are quantified using cerebral magnetic resonance.


Eligibility Criteria:
INCLUSION CRITERIA:

* Submitted to psychiatric hospital, district psychiatry or private psychiatrist because of major depressive disorder.
* Meets the criteria for Major Depressive Disorder, Single Episode as defined in the Diagnostic and Statistical Manual, fourth edition (DSM-IV) and the International Classification of Diseases (ICD-10).
* Age 50-70 years.
* Written informed consent.
* Caucasian.

EXCLUSION CRITERIA:

* Known, or anamnestic/objective signs of, organic brain disease.
* Organic, including symptomatic, mental disorders as (ICD-10: F00-F09).
* Dependence syndrome within the last 5 years (ICD-10: F1x.2) or current harmful use (ICD-10: F1x.1) of alcohol or other psychoactive substances.
* Schizophrenia, schizotypal and delusional disorders (ICD-10: F20-F29).
* Subject to force of law according to the danish law on psychiatry.
* Present risk of suicide.
* Previous cranial trauma resulting in unconsciousness for more than 2 minutes.
* Medical history of renal failure.
* Other conditions which contraindicate specific procedures in the project.
* Other conditions deemed to prevent the subject from completing the examination program.
* Does not want to participate.